课题基金 / 基金详情

Study of genetic changes in chronic myeloid leukemia in Vietnam

Study of genetic changes in chronic myeloid leukemia in Vietnam
越南慢性粒细胞白血病基因变化研究
批准号:
14571007
负责人:
SATO Yuko
金额:
$1.79万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

SATO Yuko的其他基金

相似基金

相关文献

中文摘要
翻译
越南战争期间,越南南部暴露在大量的二恶英中,这是一种强烈的人类致癌物。虽然我们观察到越南南部CML患者的生存期(13.1±11.6个月)比越南北部CML患者的生存期(31.5±7.1个月)短得多,但原因尚不清楚。在此,我们报告47例CML患者的细胞遗传学和分子检查结果。细胞遗传学上,44例(93.6%)发生费城(Ph)易位。在其余的Ph(-)型CML患者中,有2例患者表现出BCR/ABL转录本,但没有BCR/ABLFISH融合信号,提示存在2个带有和不带有BCR/ABL融合基因的克隆。令人惊讶的是,在17例(36.2%)患者中(诊断时4例,慢性期11例,加速期2例),我们发现了几种独特的继发染色体异常,包括13三体、部分13三体以及1p、3p、6p、7p、10p和11p异常,这与母细胞期CML观察到的所谓“附加染色体异常”不同。在11例(23.4%)FISH患者中发现Ph易位伴der(9)缺失。其中2例有2个克隆,有和没有der(9)缺失,这表明在疾病进展过程中,一部分患者会发生der(9)缺失。这些观察结果表明,先前存在的遗传不稳定性会诱发各种继发染色体异常和多克隆,导致生存时间缩短。
英文摘要
During the Vietnam War, southern Vietnam was exposed to a large amount of dioxin, a strong human carcinogen. Although we have observed much shorter survival in southern Vietnamese CML patients (13.1±11.6 mo) compared with that of northern Vietnamese CML patients (31.5 ±7.1 mo), the cause remains to be clarified.Here, we report cytogenetic and molecular findings of 47 CML patients. Cytogenetically, the Philadelphia (Ph) translocation was found in 44 (93.6%). Among the remaining patients with Ph(-) CML, 2 exhibited BCR/ABL transcripts but no BCR/ABLFISH fusion signals, suggesting the existence of 2 clones with and without BCR/ABL fusion gene. Surprisingly, in 17 patients (36.2%) (4 at diagnosis, 11 during chronic phase and 2 in accelerated phase), we have found several unique secondary chromosome abnormalities including trisomy 13, partial trisomy 13, and abnormalities of 1p, 3p, 6p, 7p, 10p and 11p, which are different from so-called "additional chromosome abnormalities" observed in blastic phase CML. The Ph translocation with der(9) deletion was found in 11 patients (23.4%) with FISH. Among them, 2 had 2 clones, with and without der(9) deletion, suggesting that der(9) deletion would occur in a subset of patients during disease progression. These observations point to pre-existing genetic instability which would induce various secondary chromosome abnormalities and multiple clones, resulting in shorter survival.
期刊论文(80)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2006
期刊: Cancer Genet Cytogenet 164
影响因子: --
作者: [Xinh PT, Vu HA, Nghia H, Binh NT, Be TV, Binh TV, Tokunaga K, Sato Y]
通讯作者: Sato Y
Identification of the breakpoints at ip36.2 and 3p2l.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) translocation at the third relapse.
在第三次复发时发生 t(1;3)(p36.2;p21.3) 易位的 AML(M3) 患者中 ip36.2 和 3p2l.3 处断点的识别。
DOI: --
发表时间: 2002
期刊: Genes Chromosom Cancer 35
影响因子: --
作者: [Tri NK]
通讯作者: Tri NK
Xinh PT, Tri NK, Nagao H, Nakazato H, Taketazu F, Fujisawa S, Yagasaki F, Chen YZ, Hayashi Y, Toyoda A, Hattori M, Sakaki Y, Tokunaga K, Sato Y.: "The breakpoints at 1p36.3 detected with BAC/PAC probes in three MDS/AML(M4) patients with t(1;3)(p36;q21) tr
Xinh PT, Tri NK, Nagao H, Nakazato H, Taketazu F, Fujisawa S, Yagasaki F, Chen YZ, Hayashi Y, Toyoda A, Hattori M, Sakaki Y, Tokunaga K, Sato Y.:“1p36.3 处的断点
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
t(1;3)(p36;p21) is a recurring therapy-related translocation.
t(1;3)(p36;p21) 是一种反复出现的治疗相关易位。
DOI: --
发表时间: 2002
期刊: Genes Chromosom Cancer 34
影响因子: --
作者: [Sato Y]
通讯作者: Sato Y
共 32 条
    Functional analysis of ETV6/ARG gene develop differentiation therapy for leukemias
    Eating behavior and fat transport from the interstine in old and obese rats
    DEVELOPMENT OF AN EDUCATIONAL SYSTEM TO FOSTER LOGICAL THINKING IN NURSING STUDENTS
    • 批准号:
      10557256
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.32万
    • 财政年份:
      1998
    • 负责人:
      SATO Yuko
    • 依托单位:
    The effect of somatosensory stimulation on the blood flow in the skeletal muscle.
    • 批准号:
      09670084
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.79万
    • 财政年份:
      1997
    • 负责人:
      SATO Yuko
    • 依托单位:
    国内基金
    海外基金
    靶向Bcr-Abl底物结合位点的新型多肽类抑制剂设计合成及其抗CML活性研究
    • 批准号:
      82373726
    • 项目类别:
      面上项目
    • 资助金额:
      49万元
    • 批准年份:
      2023
    • 负责人:
      潘晓艳
    • 依托单位:
    BCR-ABL靶向的蛋白酶体降解剂(PROTACs)对抗CML临床耐药机制和作用研究
    • 批准号:
      --
    • 项目类别:
      --
    • 资助金额:
      55万元
    • 批准年份:
      2021
    • 负责人:
      高红英
    • 依托单位:
    BCR-ABL靶向的蛋白酶体降解剂(PROTACs)对抗CML临床耐药机制和作用研究
    • 批准号:
      82170169
    • 项目类别:
      面上项目
    • 资助金额:
      55.00万元
    • 批准年份:
      2021
    • 负责人:
      高红英
    • 依托单位:
    Rapsyn介导的CML干细胞中BCR-ABL ufmylation修饰及其干预策略
    • 批准号:
      81973386
    • 项目类别:
      面上项目
    • 资助金额:
      54.0万元
    • 批准年份:
      2019
    • 负责人:
      陈依军
    • 依托单位: